background
object
interferon
alpha
ifna
known
antivir
agent
doubleblind
placebocontrol
clinic
trial
conduct
investig
use
lowdos
oral
interferon
alpha
prevent
acut
viral
respiratori
ill
method
two
hundr
healthi
adult
age
year
enrol
complet
weekli
health
data
questionnair
monitor
symptom
impact
respiratori
ill
serum
sampl
test
antibodi
influenza
common
respiratori
virus
result
lowdos
oral
ifna
prophylaxi
reduc
incid
impact
acut
respiratori
ill
ari
impact
ill
daili
activ
post
hoc
analysi
particip
subgroup
howev
identifi
signific
reduct
incid
ari
report
male
age
year
receiv
season
influenza
vaccin
interferon
alpha
prophylaxi
signific
impact
report
moderatetosever
feverish
studi
popul
seroposit
particip
ifn
group
like
report
asymptomat
mild
symptom
compar
placebo
group
like
report
stronger
symptom
conclus
lowdos
oral
ifna
prophylaxi
effect
limit
overal
incid
ari
studi
popul
howev
evid
prophylaxi
reduc
sever
symptom
benefici
effect
subpopul
includ
receiv
season
trival
influenza
vaccin
pleas
cite
paper
bennett
et
al
lowdos
oral
interferon
alpha
prophylaxi
viral
respiratori
ill
doubleblind
parallel
control
trial
influenza
pandem
year
influenza
respiratori
virus
season
influenza
caus
million
case
sever
febril
ill
death
year
intern
major
econom
burden
highest
diseas
burden
occur
older
individu
underli
chronic
ill
immunosuppress
infant
pregnant
women
influenza
vaccin
primari
intervent
reduct
incid
sever
influenza
infect
howev
mani
atrisk
individu
get
vaccin
vulner
group
elderli
immunosuppress
respond
poorli
vaccin
furthermor
protect
reduc
mismatch
circul
strain
vaccin
event
newli
emerg
influenza
strain
recent
pandem
vaccin
may
unavail
sever
month
antivir
drug
avail
protein
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
zanamivir
oseltamivir
shorten
reduc
sever
ill
may
reduc
complic
need
commenc
within
hour
onset
resist
alreadi
emerg
strain
remain
potenti
risk
futur
therefor
import
continu
investig
new
therapi
use
independ
conjunct
treatment
current
avail
product
type
ifn
critic
earli
host
respons
viral
infect
induc
antivir
gene
product
modul
downstream
innat
adapt
immun
respons
despit
broad
therapeut
potenti
current
use
ifn
larg
restrict
highdos
parenter
therapi
treatment
sever
infect
hepat
b
c
oral
ifn
administr
low
dose
believ
mimic
natur
mode
action
result
concentr
type
ifn
local
nasal
mucosa
similar
induc
exposur
respiratori
virus
investig
physiolog
level
endogen
type
ifn
viral
infect
report
level
iuml
iuml
nasal
secret
iuml
serum
approxim
time
less
dose
deliv
parenter
treatment
hepat
c
use
ifn
low
dose
mean
treatment
rel
inexpens
experi
ifn
treatment
influenza
inconsist
earli
report
russia
use
intranas
interferon
indic
could
effect
prophylaxi
treatment
followup
studi
conduct
elsewher
found
minim
benefit
unaccept
side
effect
highdos
intranas
ifn
intern
unit
iu
use
intranas
ifn
prophylaxi
shown
effect
reduc
incid
rhinoviru
infect
demonstr
doserespons
relationship
increas
dose
associ
increas
efficaci
also
increas
local
advers
effect
mainli
irrit
nasal
mucosa
interestingli
data
murin
studi
suggest
lowdos
ifn
effect
higher
dose
indic
lowdos
oral
ifn
may
effect
despit
disappoint
previou
experi
mechan
underli
effect
lowdos
oral
ifn
therapi
unknown
murin
studi
shown
ifna
administ
oral
caviti
retain
tissu
proxim
lymphoid
region
includ
posterior
nasal
caviti
posterior
tongu
small
intestin
type
interferon
receptor
also
present
high
concentr
oropharyng
caviti
elsewher
gastrointestin
tract
hypothes
ifn
deliv
oral
rout
bind
receptor
special
cell
oral
andor
pharyng
caviti
elicit
therapeut
immun
respons
without
need
deliveri
exogen
ifn
system
circul
oral
administr
lowdos
recombin
ifn
shown
produc
immunomodulatori
effect
anim
studi
human
clinic
trial
reduc
influenza
mortal
mous
model
well
toler
trial
evid
signific
advers
effect
therefor
undertook
clinic
trial
examin
efficaci
lowdos
oral
ifn
prevent
acut
respiratori
ill
winter
influenza
season
western
australia
coincid
emerg
pandem
viru
phase
random
doubleblind
placebocontrol
clinic
trial
conduct
singl
site
perth
western
australia
purpos
studi
evalu
efficaci
oncedaili
lozeng
contain
lowdos
ifna
prevent
acut
respiratori
viral
ill
healthi
adult
age
year
subject
provid
written
inform
consent
studi
approv
sir
charl
gardner
hospit
human
research
ethic
committe
perth
western
australia
conduct
accord
current
revis
declar
helsinki
revis
south
africa
local
law
regul
trial
regist
australian
new
zealand
clinic
trial
registri
http
wwwanzctrorgau
http
clinicaltrialsgov
primari
endpoint
studi
incid
acut
respiratori
ill
ari
defin
presenc
one
symptom
sever
rate
moder
sever
treatment
period
lozeng
contain
anhydr
crystallin
maltos
magnesium
state
activ
lozeng
contain
iu
natur
human
interferon
alpha
ratio
ifna
ifna
prepar
hbl
hayabashi
biochem
lab
okayama
japan
suppli
amarillo
bioscienc
inc
amarillo
tx
usa
activ
lozeng
retain
full
potenc
least
year
refriger
year
store
room
temperatur
ifna
placebo
lozeng
ident
appear
tast
odour
formal
test
blind
perform
trial
howev
hbl
ifn
lozeng
prepar
use
previou
clinic
trial
bia
report
note
particip
random
one
two
treatment
group
iu
ifna
lozeng
placebo
lozeng
treatment
period
particip
ask
dissolv
one
lozeng
mouth
morn
complianc
monitor
use
weekli
health
data
questionnair
particip
ask
report
mani
day
taken
trial
medic
count
confirm
end
studi
particip
return
trial
medic
remain
lozeng
count
healthi
adult
age
year
recruit
perth
metropolitan
area
email
newspap
advertis
medic
influenza
vaccin
histori
baselin
full
blood
pictur
renal
function
test
liver
function
test
bhcg
femal
lipid
profil
taken
volunt
exclud
found
increas
risk
sever
complic
influenza
histori
chronic
respiratori
condit
chronic
hepat
b
hepat
c
infect
sever
depress
pregnant
signific
abnorm
laboratori
result
abnorm
lipid
profil
deem
trial
clinician
subject
receiv
season
influenza
vaccin
elig
enrol
studi
particip
receiv
pandem
influenza
vaccin
prior
treatment
period
studi
amarillo
bioscienc
inc
carri
studi
drug
random
blind
total
studi
id
number
alloc
use
label
individu
studi
drug
contain
held
pharmaci
depart
sir
charl
gairdner
hospit
drug
dispens
particip
follow
random
use
randomli
permut
block
four
subject
particip
assign
one
two
group
iu
ifna
ii
placebo
recruit
enrol
progress
first
particip
start
midmay
final
particip
complet
treatment
period
midnovemb
onlin
weekli
health
data
questionnair
adapt
wisconsin
upper
respiratori
daili
symptom
report
survey
use
collect
inform
incid
sever
impact
ari
particip
report
symptom
associ
acut
respiratori
ill
cough
sore
throat
scratchi
throat
hoars
runni
nose
plug
nose
sneez
headach
bodi
ach
chill
fever
head
congest
chest
congest
sever
scale
use
rang
absent
mild
mild
moder
sever
particip
ask
rank
sever
ill
base
follow
definit
mild
symptom
caus
minim
discomfort
interfer
signific
manner
normal
activ
moder
symptom
suffici
uncomfort
produc
impair
normal
activ
sever
symptom
incapacit
prevent
particip
normal
activ
particip
ask
rate
symptom
felt
due
cold
influenza
believ
headach
due
caus
cold
influenza
need
score
particip
also
ask
report
impact
ill
daili
activ
number
day
felt
sick
andor
miss
work
whether
visit
medic
practition
andor
pharmaci
whether
took
medic
whether
skip
plan
activ
serum
sampl
collect
particip
time
initi
screen
treatment
period
influenza
subtypespecif
hemagglutin
inhibit
hi
titr
antibodi
pandem
influenza
acalifornia
season
influenza
season
influenza
perform
collabor
centr
refer
research
influenza
melbourn
australia
antibodi
influenza
b
adenoviru
respiratori
syncyti
viru
parainfluenza
virus
type
detect
complement
fixat
titr
cft
pathwest
fourfold
greater
increas
titr
taken
indic
infect
viru
trial
period
pretrial
influenza
immun
hi
titr
influenza
subtyp
cft
virus
regard
signific
particip
vaccin
season
influenza
elig
enrol
studi
exclud
serolog
analysi
monoval
pandem
vaccin
made
avail
adult
septemb
particip
report
whether
receiv
vaccin
none
receiv
pandem
vaccin
treatment
period
three
particip
receiv
vaccin
treatment
period
collect
posttreat
sera
particip
exclud
serolog
analysi
efficaci
analys
carri
intenttotreat
itt
popul
consist
patient
random
took
least
one
dose
studi
medic
incid
ari
calcul
proport
patient
experienc
one
episod
ari
treatment
period
analys
use
binari
logist
regress
model
compar
two
treatment
group
adjust
season
influenza
vaccin
statu
sex
age
rate
ari
defin
number
episod
per
particip
experienc
treatment
period
pearson
chisquar
test
use
determin
signific
omnibu
test
use
identifi
subhypothes
post
hoc
investig
sex
age
season
influenza
vaccin
statu
interact
explor
compar
adjust
odd
ratio
safeti
analysi
includ
pearson
chisquar
fisher
exact
test
compar
treatment
group
proport
subject
report
advers
event
report
sever
level
advers
event
report
one
seriou
advers
event
fail
complet
week
treatment
treatment
group
also
compar
chang
full
blood
count
serum
chemistri
variabl
time
screen
end
treatment
analysi
varianc
analys
perform
use
spss
softwar
pasw
statist
spss
inc
chicago
il
usa
one
hundr
ninetyeight
particip
tabl
complet
total
weekli
health
data
questionnair
repres
expect
return
total
particip
complet
treatment
cours
within
popul
studi
drug
complianc
averag
median
age
studi
popul
year
rang
year
femal
case
acut
respiratori
ill
ari
defin
report
one
symptom
sever
rate
moder
sever
treatment
period
studi
particip
report
ari
occur
placebo
group
mean
ae
per
particip
occur
ifn
group
mean
ae
per
particip
p
also
signific
differ
proport
particip
report
ari
two
treatment
group
figur
post
hoc
analysi
demograph
subgroup
perform
result
report
post
hoc
subgroup
analysi
base
sex
figur
age
figur
season
influenza
vaccin
statu
figur
perform
examin
differ
incid
ari
ifn
placebo
group
prophylaxi
iu
ifna
significantli
reduc
incid
male
age
year
receiv
southern
hemispher
season
influenza
vaccin
sex
age
vaccin
statu
treatment
group
b
c
figur
proport
particip
treatment
group
report
one
episod
acut
respiratori
ill
ari
studi
period
episod
ari
defin
respiratori
symptom
report
within
given
weekli
health
data
report
rate
moder
sever
error
bar
indic
confid
interv
binari
logist
regress
model
use
adjust
sex
age
season
influenza
vaccin
statu
includ
regress
model
correct
multipl
comparison
particip
ask
report
total
symptom
associ
ari
determin
whether
overal
effect
symptom
perform
areaunderthecurv
auc
analysi
total
weekli
symptom
score
particip
independ
whether
met
criteria
ari
mean
auc
valu
ae
observ
placebo
group
ae
interferon
group
indic
signific
differ
treatment
group
p
incid
sever
individu
symptom
also
analys
signific
differ
seen
overal
incid
symptom
report
two
treatment
group
moder
sever
symptom
feverish
significantli
reduc
incid
proport
ae
particip
placebo
group
ae
ifn
group
p
reduct
report
feverish
observ
across
sex
age
vaccin
statu
subgroup
signific
differ
observ
report
moderatetosever
symptom
variabl
measur
howev
statist
nonsignific
trend
reduct
observ
two
symptom
head
congest
reduc
ae
ae
p
sore
throat
reduc
ae
ae
p
ifn
group
reduct
observ
age
year
male
vaccin
season
influenza
vaccin
sex
age
season
influenza
vaccin
statu
treatment
group
interact
includ
regress
model
correct
multipl
comparison
secondari
outcom
studi
categor
three
group
neg
impact
due
cold
flu
serolog
advers
event
interferon
prophylaxi
impact
number
day
particip
report
miss
work
take
cold
flu
medic
number
medic
practition
visit
pharmaci
visit
day
spent
feel
sick
number
day
plan
activ
skip
due
cold
influenza
symptom
total
pair
particip
sampl
avail
analysi
ifn
treatment
group
placebo
group
seven
particip
sampl
exclud
due
seroconvers
result
season
n
pandem
n
influenza
vaccin
trial
particip
ifn
treatment
group
infect
respiratori
virus
particip
placebo
group
infect
respiratori
virus
tabl
overal
incid
influenza
noninfluenza
infect
detect
serolog
ifn
placebo
group
figur
serolog
data
correl
report
moderatetosever
symptom
defin
ari
collect
weekli
health
data
questionnair
proport
seroposit
particip
report
moderatetosever
symptom
placebo
recipi
compar
ifn
recipi
p
figur
result
indic
ifn
reduc
incid
serolog
proven
infect
significantli
reduc
incid
moder
sever
ill
analysi
earli
studi
termin
includ
random
subject
otherwis
safeti
analys
includ
subject
took
least
one
dose
studi
drug
treatment
group
compar
chang
full
blood
count
serum
chemistri
variabl
screen
end
treatment
analysi
varianc
chisquar
fisher
exact
test
use
compar
treatment
group
proport
subject
report
advers
event
ii
report
sever
level
mild
moder
sever
advers
event
iii
report
one
seriou
advers
event
iv
fail
complet
week
treatment
overal
rate
advers
event
low
averag
advers
event
report
per
placebotr
subject
advers
event
report
per
ifntreat
subject
week
studi
treatment
followup
proport
subject
group
report
one
advers
event
treatment
signific
differ
group
proport
subject
report
one
mild
moder
sever
advers
event
either
overal
particular
advers
event
advers
event
report
greatest
frequenc
hay
fever
particip
diarrhoea
particip
headach
associ
cold
flu
symptom
particip
signific
differ
proport
ifnor
placebotr
particip
report
symptom
total
random
subject
complet
week
treatment
treatment
group
differ
significantli
rate
earli
termin
overal
due
advers
event
singl
seriou
advers
event
report
group
result
inpati
hospit
event
unrel
respiratori
ill
neither
deem
investig
blind
relat
studi
drug
subject
placebo
group
underw
emerg
appendectomi
subject
ifn
group
requir
emerg
haemorrhoidectomi
subject
abl
complet
studi
addit
clinic
meaning
advers
laboratori
find
blood
count
serum
chemistri
variabl
assess
variabl
significantli
differ
treatment
group
week
mean
creatinin
level
placebo
group
report
mean
level
lm
ae
ifn
group
report
mean
level
lm
ae
p
refer
rang
variabl
lm
male
lm
femal
given
small
absolut
differ
mean
creatinin
level
group
fact
mean
chang
level
differ
significantli
group
find
believ
clinic
meaning
studi
investig
efficaci
lowdos
oral
ifna
iu
protect
acut
viral
respiratori
ill
oral
ifna
prophylaxi
significantli
reduc
incid
ari
figur
healthi
adult
age
year
old
reduc
weekli
symptom
score
particip
reduc
overal
sever
symptom
howev
individu
symptom
report
show
reduct
incid
moderatetosever
episod
feverish
iu
ifna
popul
trend
also
observ
reduct
head
congest
p
sore
throat
p
studi
also
found
overal
incid
ari
reduc
ifn
prophylaxi
post
hoc
analysi
data
demonstr
protect
effect
male
age
year
receiv
southern
hemispher
season
influenza
vaccin
figur
independ
predictor
benefici
ifna
effect
also
ifna
treatment
group
significantli
fewer
vaccin
particip
compar
placebo
group
tabl
may
bias
ifna
effect
studi
age
effect
chose
analys
effect
ifna
particip
age
year
separ
repres
approxim
studi
popul
also
recogn
increas
risk
sever
complic
influenza
insuffici
number
look
older
age
group
age
year
sex
age
differ
effect
type
ifn
hepat
c
cytokinebas
immun
respons
previous
report
mechan
behind
observ
unknown
appar
effect
ifna
particip
receiv
season
vaccin
intrigu
suggest
ifna
may
improv
crossprotect
pandem
influenza
strain
follow
season
influenza
vaccin
report
season
trival
vaccin
also
afford
crossprotect
confirm
pandem
influenza
ill
vaccin
also
shown
prior
exposur
pandem
influenza
strain
circul
establish
immunolog
memori
older
popul
provid
clinic
protect
sever
ill
mechan
underli
effect
unknown
anim
studi
suggest
immunolog
prime
crossreact
memori
cell
cytolyt
cell
other
propos
agre
ifn
like
act
adjuv
enhanc
dendrit
cell
function
drive
humor
cellmedi
crossprotect
studi
design
confirm
investig
effect
requir
weekli
health
questionnair
also
use
assess
impact
ari
daili
life
find
benefit
ifna
prophylaxi
paramet
assess
tabl
evid
iu
ifna
prophylaxi
reduc
incid
serolog
confirm
infect
influenza
respiratori
virus
contrast
recent
studi
report
human
nose
throat
spray
prevent
acut
viral
respiratori
infect
militari
recruit
may
due
differ
ifn
dose
rout
administr
studi
popul
studi
design
conduct
studi
period
limit
diagnost
test
studi
use
igm
detect
singl
serum
sampl
may
significantli
underestim
infect
rate
adult
howev
find
patient
serolog
confirm
respiratori
viral
infect
take
ifna
significantli
lower
incid
moder
sever
symptom
figur
similar
result
previous
report
follow
intranas
administr
ifna
iuday
reduct
serolog
influenza
infect
clinic
ill
milder
interferon
group
find
suggest
lowdos
oral
ifna
prophylaxi
reduc
risk
infect
influenza
respiratori
virus
appear
amelior
symptom
consist
find
signific
reduct
feverish
ifna
prophylaxi
unfortun
unabl
carri
direct
test
virus
pcr
therefor
unabl
assess
role
respiratori
viru
infect
could
detect
serolog
rhinovirus
coronavirus
human
metapneumoviru
also
directli
measur
endogen
local
system
ifn
level
recent
murin
studi
found
lowdos
intranas
ifna
treatment
protect
lethal
influenza
challeng
also
report
lowdos
ifn
treatment
addit
effect
ifna
induct
enhanc
product
interferonstimul
gene
detect
lung
summari
result
show
iu
ifna
administ
via
oral
rout
effect
limit
overal
incid
ari
studi
popul
reduc
impact
respiratori
viru
infect
daili
activ
howev
find
evid
reduc
sever
ill
though
studi
effect
suffici
reduc
impact
daili
activ
furthermor
benefit
ifna
prophylaxi
may
substanti
certain
subpopul
male
age
year
receiv
season
influenza
vaccin
studi
would
help
clarifi
whether
ifna
reduc
sever
ill
complic
influenza
respiratori
infect
elderli
highrisk
group
addit
need
determin
potenti
ifna
enhanc
vaccineinduc
protect
influenza
